Indeed, a recent phase I clinical trial in six patients with multifocal recurrent GBM showed that the intrathecal injection of bivalent CAR-T cells targeting both IL-13Rα2 and EGFR led to tumor reduction in all patients, although none met the criteria for ORR [68]. This evidence concerns the gene IL13RA2 and glioblastoma.